tetano
Editor, Senior Moderator
Arch Med Res
. 2020 Jun 19;S0188-4409(20)30590-7.
doi: 10.1016/j.arcmed.2020.06.012. Online ahead of print.
Targeting Cytokine Storm to Manage Patients with COVID-19: A Mini-Review
Neda Roshanravan[SUP] 1 [/SUP], Farhad Seif[SUP] 2 [/SUP], Alireza Ostadrahimi[SUP] 3 [/SUP], Mahboub Pouraghaei[SUP] 4 [/SUP], Samad Ghaffari[SUP] 5 [/SUP]
Affiliations
Abstract
Corona Virus Disease 2019 (COVID-19) pandemic is rapidly spreading all over the world. Excessive immune responses trigger life-threatening cytokine release syndrome (CRS) which can result in overproduction of pro-inflammatory cytokines including tumor necrosis factor alpha (TNFα), interleukin-6 (IL-6), and IL-1β with different pro-inflammatory roles. Anecdotal evidence suggests that the modulation of systemic immune responses may have a potential role in the treatment of patients with COVID-19. Given the importance of the issue and the lack of therapeutic treatment or vaccine; anti-cytokine therapy such as IL-6, TNFα and IL-1 antagonists have been suggested for the alleviation of hyper-inflammation status in these patients. In this mini-review, we addressed the inflammatory pathways of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its relationship with the host cytokine storm. Furthermore, the proposed therapeutic options to reverse hyper-inflammation in infected patients were mentioned.
Keywords: COVID-19; Cytokine storm; IL-1β; IL-6; SARS-CoV-2; TNFα.
. 2020 Jun 19;S0188-4409(20)30590-7.
doi: 10.1016/j.arcmed.2020.06.012. Online ahead of print.
Targeting Cytokine Storm to Manage Patients with COVID-19: A Mini-Review
Neda Roshanravan[SUP] 1 [/SUP], Farhad Seif[SUP] 2 [/SUP], Alireza Ostadrahimi[SUP] 3 [/SUP], Mahboub Pouraghaei[SUP] 4 [/SUP], Samad Ghaffari[SUP] 5 [/SUP]
Affiliations
- PMID: 32682575
- DOI: 10.1016/j.arcmed.2020.06.012
Abstract
Corona Virus Disease 2019 (COVID-19) pandemic is rapidly spreading all over the world. Excessive immune responses trigger life-threatening cytokine release syndrome (CRS) which can result in overproduction of pro-inflammatory cytokines including tumor necrosis factor alpha (TNFα), interleukin-6 (IL-6), and IL-1β with different pro-inflammatory roles. Anecdotal evidence suggests that the modulation of systemic immune responses may have a potential role in the treatment of patients with COVID-19. Given the importance of the issue and the lack of therapeutic treatment or vaccine; anti-cytokine therapy such as IL-6, TNFα and IL-1 antagonists have been suggested for the alleviation of hyper-inflammation status in these patients. In this mini-review, we addressed the inflammatory pathways of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its relationship with the host cytokine storm. Furthermore, the proposed therapeutic options to reverse hyper-inflammation in infected patients were mentioned.
Keywords: COVID-19; Cytokine storm; IL-1β; IL-6; SARS-CoV-2; TNFα.